Daito Pharmaceutical Co.,Ltd. (TYO:4577)
Japan
· Delayed Price · Currency is JPY 2,094.00
-56.00 (-2.60%)
Mar 10, 2025, 3:30 PM JST
Daito Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is June - May.
Millions JPY. Fiscal year is Jun - May.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Nov '24 Nov 30, 2024 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 | May '21 May 31, 2021 | May '20 May 31, 2020 | 2019 - 2015 |
| Revenue | 47,369 | 46,895 | 45,101 | 43,464 | 48,714 | 44,991 | Upgrade
|
| Revenue Growth (YoY) | 3.33% | 3.98% | 3.77% | -10.78% | 8.27% | 9.38% | Upgrade
|
| Cost of Revenue | 38,341 | 37,056 | 34,770 | 32,005 | 37,922 | 35,507 | Upgrade
|
| Gross Profit | 9,028 | 9,839 | 10,331 | 11,459 | 10,792 | 9,484 | Upgrade
|
| Selling, General & Admin | 3,438 | 3,431 | 3,082 | 3,004 | 2,719 | 2,614 | Upgrade
|
| Research & Development | 2,349 | 2,349 | 1,865 | 1,749 | 2,032 | 1,400 | Upgrade
|
| Operating Expenses | 5,952 | 5,945 | 5,119 | 4,891 | 4,876 | 4,122 | Upgrade
|
| Operating Income | 3,076 | 3,894 | 5,212 | 6,568 | 5,916 | 5,362 | Upgrade
|
| Interest Expense | -83 | -41 | -12 | -9 | -8 | -12 | Upgrade
|
| Interest & Investment Income | 67 | 65 | 57 | 55 | 64 | 68 | Upgrade
|
| Currency Exchange Gain (Loss) | 6 | -23 | -91 | 22 | 66 | 14 | Upgrade
|
| Other Non Operating Income (Expenses) | 19 | 29 | 4 | 93 | 28 | 31 | Upgrade
|
| EBT Excluding Unusual Items | 3,078 | 3,924 | 5,170 | 6,729 | 6,066 | 5,463 | Upgrade
|
| Gain (Loss) on Sale of Investments | 735 | 326 | -87 | 47 | 1 | 134 | Upgrade
|
| Asset Writedown | -165 | -165 | -17 | -56 | -314 | -156 | Upgrade
|
| Other Unusual Items | 134 | 134 | 11 | - | 120 | 154 | Upgrade
|
| Pretax Income | 3,782 | 4,219 | 5,077 | 6,720 | 5,873 | 5,595 | Upgrade
|
| Income Tax Expense | 1,380 | 1,040 | 1,549 | 2,092 | 1,716 | 1,670 | Upgrade
|
| Earnings From Continuing Operations | 2,402 | 3,179 | 3,528 | 4,628 | 4,157 | 3,925 | Upgrade
|
| Minority Interest in Earnings | 249 | 116 | 72 | 40 | 89 | 19 | Upgrade
|
| Net Income | 2,651 | 3,295 | 3,600 | 4,668 | 4,246 | 3,944 | Upgrade
|
| Net Income to Common | 2,651 | 3,295 | 3,600 | 4,668 | 4,246 | 3,944 | Upgrade
|
| Net Income Growth | -21.80% | -8.47% | -22.88% | 9.94% | 7.66% | 12.27% | Upgrade
|
| Shares Outstanding (Basic) | 15 | 16 | 16 | 15 | 15 | 14 | Upgrade
|
| Shares Outstanding (Diluted) | 15 | 16 | 16 | 15 | 15 | 14 | Upgrade
|
| Shares Change (YoY) | -2.32% | -0.86% | 3.38% | 1.94% | 6.41% | 2.53% | Upgrade
|
| EPS (Basic) | 171.74 | 209.99 | 227.64 | 304.90 | 282.72 | 281.45 | Upgrade
|
| EPS (Diluted) | 171.74 | 209.99 | 227.43 | 304.90 | 282.72 | 279.49 | Upgrade
|
| EPS Growth | -19.94% | -7.67% | -25.41% | 7.85% | 1.16% | 9.51% | Upgrade
|
| Free Cash Flow | -2,405 | -1,038 | -1,350 | -257 | -1,136 | 1,575 | Upgrade
|
| Free Cash Flow Per Share | -155.80 | -66.15 | -85.29 | -16.79 | -75.64 | 111.60 | Upgrade
|
| Dividend Per Share | 65.000 | 60.000 | 54.545 | 45.455 | 41.818 | 36.364 | Upgrade
|
| Dividend Growth | 13.49% | 10.00% | 20.00% | 8.70% | 15.00% | 5.26% | Upgrade
|
| Gross Margin | 19.06% | 20.98% | 22.91% | 26.36% | 22.15% | 21.08% | Upgrade
|
| Operating Margin | 6.49% | 8.30% | 11.56% | 15.11% | 12.14% | 11.92% | Upgrade
|
| Profit Margin | 5.60% | 7.03% | 7.98% | 10.74% | 8.72% | 8.77% | Upgrade
|
| Free Cash Flow Margin | -5.08% | -2.21% | -2.99% | -0.59% | -2.33% | 3.50% | Upgrade
|
| EBITDA | 7,141 | 7,553 | 9,082 | 9,881 | 9,070 | 8,312 | Upgrade
|
| EBITDA Margin | 15.08% | 16.11% | 20.14% | 22.73% | 18.62% | 18.47% | Upgrade
|
| D&A For EBITDA | 4,065 | 3,659 | 3,870 | 3,313 | 3,154 | 2,950 | Upgrade
|
| EBIT | 3,076 | 3,894 | 5,212 | 6,568 | 5,916 | 5,362 | Upgrade
|
| EBIT Margin | 6.49% | 8.30% | 11.56% | 15.11% | 12.14% | 11.92% | Upgrade
|
| Effective Tax Rate | 36.49% | 24.65% | 30.51% | 31.13% | 29.22% | 29.85% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.